Classement en actions
#33866
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company... 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Prix de l'action
$0.5475
Dernière synchronisation: 2026-08-14
Capitalisation boursière
$6.71M
Changement (1 jour)
5.57%
Échange 20/20 Biolabs Inc. (AIDX)
Le prix AIDX avec la capitalisation boursière de B
Capitalisation boursière de 20/20 Biolabs Inc.(AIDX)
Capitalisation boursière: $6.71M
En August 2026, 20/20 Biolabs Inc. a une capitalisation boursière de $6.71M. Cela fait de 20/20 Biolabs Inc. la 33866th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de 20/20 Biolabs Inc. du 2026 au 2026
AIDX par rapport au top 5 des plus populaires stocks
| Prix pour AIDX |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.452T
|
+81,276,656.64%
|
|
|
|
|
$4.490T
|
+66,937,378.02%
|
|
|
|
|
$4.162T
|
+62,053,302.40%
|
|
|
|
|
$3.676T
|
+54,807,023.79%
|
|
|
|
|
$2.833T
|
+42,235,061.84%
|
